{"title":"糖皮质激素导致的月牙样面容与糖尿病和身体形象障碍的发展有关。","authors":"Takahiro Tsutsumi, Daiki Nakagomi, Kei Kobayashi, Shunichiro Hanai, Yoshiaki Kobayashi, Ryosuke Ito, Toshihisa Ishii, Hideyuki Okuma, Hiroyuki Uchinuma, Masashi Ichijo, Kyoichiro Tsuchiya","doi":"10.1210/jendso/bvae036","DOIUrl":null,"url":null,"abstract":"<p><strong>Context: </strong>Moon-like facies (MLF) are a typical side effect of glucocorticoid (GC) therapy; however, its predisposing factors, relationship with GC-induced complications, and effects on body image are not well understood.</p><p><strong>Objective: </strong>This study aimed to determine the predisposing factors for MLF during GC therapy; its association with GC-induced diabetes, hypertension, and dyslipidemia; and its effects on body image.</p><p><strong>Methods: </strong>This prospective observational study spanned 24 weeks and targeted patients who received GC therapy at the University of Yamanashi Hospital from June 2020 to August 2022. The MLF was defined based on the following 3 factors: (1) an increase in facial measurement lengths, (2) subjective facial changes by patients' self-assessment using a visual analog scale; (3) objective and qualitative facial changes assessed by physicians. We examined the predisposing factors for MLF and the association of MLF with GC-induced diabetes, hypertension, dyslipidemia, and body image.</p><p><strong>Results: </strong>The cumulative incidence rate of MLF at 24 weeks was 37.6%. Predisposing factors for MLF were an initial oral prednisolone dosage of ≥ 30 mg/day [odds ratio (OR) 63.91, 95% confidence interval (CI) 5.82-701.81] and female (OR 6.66, 95% CI 1.35-32.79). MLF showed a significant association with the onset of GC-induced diabetes (OR 6.58, 95% CI 1.25-34.74). MLF was also an independent factor contributing to body image disturbance (β = -18.94, <i>P</i> = .01).</p><p><strong>Conclusion: </strong>MLF contributes to body image disturbance and is associated with the development of GC-induced diabetes; therefore, it is clinically important as a physical manifestation of GC therapy.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"8 5","pages":"bvae036"},"PeriodicalIF":3.0000,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10928504/pdf/","citationCount":"0","resultStr":"{\"title\":\"Moon-like Facies by Glucocorticoid Is Associated With the Development of Diabetes and Body Image Disturbance.\",\"authors\":\"Takahiro Tsutsumi, Daiki Nakagomi, Kei Kobayashi, Shunichiro Hanai, Yoshiaki Kobayashi, Ryosuke Ito, Toshihisa Ishii, Hideyuki Okuma, Hiroyuki Uchinuma, Masashi Ichijo, Kyoichiro Tsuchiya\",\"doi\":\"10.1210/jendso/bvae036\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Context: </strong>Moon-like facies (MLF) are a typical side effect of glucocorticoid (GC) therapy; however, its predisposing factors, relationship with GC-induced complications, and effects on body image are not well understood.</p><p><strong>Objective: </strong>This study aimed to determine the predisposing factors for MLF during GC therapy; its association with GC-induced diabetes, hypertension, and dyslipidemia; and its effects on body image.</p><p><strong>Methods: </strong>This prospective observational study spanned 24 weeks and targeted patients who received GC therapy at the University of Yamanashi Hospital from June 2020 to August 2022. The MLF was defined based on the following 3 factors: (1) an increase in facial measurement lengths, (2) subjective facial changes by patients' self-assessment using a visual analog scale; (3) objective and qualitative facial changes assessed by physicians. We examined the predisposing factors for MLF and the association of MLF with GC-induced diabetes, hypertension, dyslipidemia, and body image.</p><p><strong>Results: </strong>The cumulative incidence rate of MLF at 24 weeks was 37.6%. Predisposing factors for MLF were an initial oral prednisolone dosage of ≥ 30 mg/day [odds ratio (OR) 63.91, 95% confidence interval (CI) 5.82-701.81] and female (OR 6.66, 95% CI 1.35-32.79). MLF showed a significant association with the onset of GC-induced diabetes (OR 6.58, 95% CI 1.25-34.74). MLF was also an independent factor contributing to body image disturbance (β = -18.94, <i>P</i> = .01).</p><p><strong>Conclusion: </strong>MLF contributes to body image disturbance and is associated with the development of GC-induced diabetes; therefore, it is clinically important as a physical manifestation of GC therapy.</p>\",\"PeriodicalId\":17334,\"journal\":{\"name\":\"Journal of the Endocrine Society\",\"volume\":\"8 5\",\"pages\":\"bvae036\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-02-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10928504/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the Endocrine Society\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1210/jendso/bvae036\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/3/12 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Endocrine Society","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1210/jendso/bvae036","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/12 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
摘要
背景:月牙样面容(MLF)是糖皮质激素(GC)治疗的一种典型副作用,但其诱发因素、与GC诱发并发症的关系以及对身体形象的影响尚不十分清楚:本研究旨在确定GC治疗期间MLF的易感因素;MLF与GC诱发的糖尿病、高血压和血脂异常的关系;以及MLF对身体形象的影响:这项前瞻性观察研究为期24周,以2020年6月至2022年8月期间在山梨大学医院接受GC治疗的患者为对象。MLF 的定义基于以下 3 个因素:(1)面部测量长度增加;(2)患者使用视觉模拟量表自我评估的主观面部变化;(3)医生评估的客观和定性面部变化。我们研究了 MLF 的诱发因素以及 MLF 与 GC 引起的糖尿病、高血压、血脂异常和身体形象的关联:结果:24周时,MLF的累积发病率为37.6%。MLF的易感因素是初始口服泼尼松龙剂量≥30毫克/天[几率比(OR)63.91,95%置信区间(CI)5.82-701.81]和女性(OR 6.66,95% CI 1.35-32.79)。MLF与GC诱发糖尿病的发病有明显关联(OR 6.58,95% CI 1.25-34.74)。MLF也是导致身体形象障碍的一个独立因素(β = -18.94,P = .01):结论:MLF会导致身体形象障碍,并与GC诱发糖尿病的发生有关;因此,作为GC治疗的一种身体表现,MLF具有重要的临床意义。
Moon-like Facies by Glucocorticoid Is Associated With the Development of Diabetes and Body Image Disturbance.
Context: Moon-like facies (MLF) are a typical side effect of glucocorticoid (GC) therapy; however, its predisposing factors, relationship with GC-induced complications, and effects on body image are not well understood.
Objective: This study aimed to determine the predisposing factors for MLF during GC therapy; its association with GC-induced diabetes, hypertension, and dyslipidemia; and its effects on body image.
Methods: This prospective observational study spanned 24 weeks and targeted patients who received GC therapy at the University of Yamanashi Hospital from June 2020 to August 2022. The MLF was defined based on the following 3 factors: (1) an increase in facial measurement lengths, (2) subjective facial changes by patients' self-assessment using a visual analog scale; (3) objective and qualitative facial changes assessed by physicians. We examined the predisposing factors for MLF and the association of MLF with GC-induced diabetes, hypertension, dyslipidemia, and body image.
Results: The cumulative incidence rate of MLF at 24 weeks was 37.6%. Predisposing factors for MLF were an initial oral prednisolone dosage of ≥ 30 mg/day [odds ratio (OR) 63.91, 95% confidence interval (CI) 5.82-701.81] and female (OR 6.66, 95% CI 1.35-32.79). MLF showed a significant association with the onset of GC-induced diabetes (OR 6.58, 95% CI 1.25-34.74). MLF was also an independent factor contributing to body image disturbance (β = -18.94, P = .01).
Conclusion: MLF contributes to body image disturbance and is associated with the development of GC-induced diabetes; therefore, it is clinically important as a physical manifestation of GC therapy.